Advertisement

Topics

Wilex AG: Subsidiary Heidelberg Pharma Signs Exclusive Multi-Target Research Agreement With Takeda For The Development Of Antibody Targeted Amanitin Conjugates

20:00 EDT 19 Jun 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Wilex AG: Subsidiary Heidelberg Pharma Signs Exclusive Multi-Target Research Agreement With Takeda For The Development Of Antibody Targeted Amanitin Conjugates

NEXT ARTICLE

More From BioPortfolio on "Wilex AG: Subsidiary Heidelberg Pharma Signs Exclusive Multi-Target Research Agreement With Takeda For The Development Of Antibody Targeted Amanitin Conjugates"

Advertisement
Quick Search
Advertisement
Advertisement